MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Checkpoint Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

4.04 0.25

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.99

Max

4.05

Pagrindiniai rodikliai

By Trading Economics

Darbuotojai

23

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+31.19% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

205M

Ankstesnė atidarymo kaina

3.79

Ankstesnė uždarymo kaina

4.04

Naujienos nuotaikos

By Acuity

50%

50%

173 / 386 reitingas Healthcare

Checkpoint Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-10 10:23; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

2024-12-14 00:24; UTC

Pagrindinės rinkos jėgos

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

2024-07-25 13:02; UTC

Pagrindinės rinkos jėgos

Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

2025-03-10 02:12; UTC

Įsigijimai, susijungimai, perėmimai

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

2025-03-10 02:12; UTC

Įsigijimai, susijungimai, perėmimai

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

2025-03-10 02:11; UTC

Įsigijimai, susijungimai, perėmimai

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

2025-03-10 02:11; UTC

Įsigijimai, susijungimai, perėmimai

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

2025-03-10 02:10; UTC

Įsigijimai, susijungimai, perėmimai

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

2025-03-10 02:10; UTC

Įsigijimai, susijungimai, perėmimai

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

2025-03-10 02:06; UTC

Įsigijimai, susijungimai, perėmimai

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Akcijų palyginimas

Kainos pokytis

Checkpoint Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

31.19% į viršų

12 mėnesių prognozė

Vidutinis 5.3 USD  31.19%

Aukščiausias 7 USD

Žemiausias 4.1 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Checkpoint Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

1

Pirkti

2

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

173 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

$

Apie bendrovę Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.